Red Yeast Rice
Red Yeast Rice (Monacolin K)
Fermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Red Yeast Rice is rice fermented with Monascus purpureus yeast, producing monacolin K — chemically identical to lovastatin. Used for centuries in Chinese medicine, it effectively lowers LDL cholesterol. However, monacolin content varies widely between products, and it carries similar risks to pharmaceutical statins. A natural option for cholesterol but requires careful sourcing and monitoring.
Mechanisms of Action
HMG-CoA Reductase Inhibition
Blocks cholesterol synthesis
Recommended Dose
1200-2400mg providing 10mg monacolin K
Optimal Timing
- Evening (cholesterol synthesis peaks at night)
Take with food
Best Form
Standardized extract with verified monacolin K content
Alternatives: Whole red yeast rice powder
CRITICAL: Monacolin K content varies 0-10mg+ between products. Choose brands that verify and disclose monacolin K content.
Duration
Minimum: 8 weeks
Optimal: 16 weeks
Cycling: Not required
Note: Take in evening with dinner, same timing as prescription statins.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
LDL Reduction
15-30% decrease in LDL cholesterol
Total Cholesterol Reduction
Reduced total cholesterol
Contraindicated — same as statins
May have same issues — try cautiously
Who Should NOT Take This
- Liver disease
- Pregnancy/nursing
- History of statin intolerance
Drug Interactions
Do NOT combine — identical mechanism, additive effects
Inhibits metabolism like lovastatin
Increased myopathy risk
Increase monacolin K levels
Risk of statin overdose, muscle damage, rhabdomyolysis
Risk of muscle damage, liver toxicity
Risk of statin overdose, muscle damage
Possible Side Effects
Tip: Same as statins — discontinue if occurs; add CoQ10
Tip: Take with food
Tip: Monitor liver enzymes
Warnings
- This IS a statin — carries same risks as prescription statins
- May deplete CoQ10 — consider supplementing
- Monitor liver enzymes periodically
- Some products contain citrinin (a toxin) — choose verified brands
- Do NOT combine with prescription statins
- Tell your doctor you're taking this
Top studies from 40+ peer-reviewed papers
Cicero AFG et al. • Nutrients (2021)
“These changes are consistent with improved cardiometabolic health.”
Key Findings:
- Armolipid Plus® was well tolerated.
- This meta-analysis demonstrates that dietary supplementation with Armolipid Plus® is associated with clinically meaningful improvements in serum lipids, glucose, and hs-CRP.
- These changes are consistent with improved cardiometabolic health.
Trogkanis E et al. • Nutrients (2024)
“Further research on specific subpopulations and outcomes could establish a consensus on determining the clinical benefits and potential risks, if any, of this nutraceutical.”
Key Findings:
- The consumption of RYR extract by people with hypercholesterolemia was associated with statistically significant reduction in total cholesterol and LDL-C, whereas it was not associated with an increase in life-threatening side effects.
- As regards the safety, RYR extract was considered a safe choice with neither threatening nor frequent side effects.
- Further research on specific subpopulations and outcomes could establish a consensus on determining the clinical benefits and potential risks, if any, of this nutraceutical.
Hernandez AV et al. • Journal of dietary supplements (2024)
“Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.”
Key Findings:
- Products with berberine alone had less robust effects on TC (MD -12.08 mg/dL [95%CI: -21.79 to -2.37]), LDL (MD -9.26 mg/dL [95%CI: -20.31 to 1.78]), and HDL (MD 1.38 mg/dL [95%CI: -1.27 to 4.03]) but TG effects were similar (MD -17.40 mg/dL [95%CI: -32.57 to -2.23]).
- Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
- Further research warranted to confirm findings
Angelopoulos N et al. • Nutrients (2023)
“Our results confirm the LDL-C-lowering properties of monacolin are clinically meaningful even in lower doses of 3 mg/day.”
Key Findings:
- LDL-C decreased by 26.46% on average (p < 0.001) during treatment with 10 mg of monacolin and by 16.77% on average during treatment with 3 mg of monacolin (p < 0.001).
- We observed a slight but significant reduction of the triglyceride levels only in the high-dose-treated group (mean -4.25%; 95% CI of mean -11.11 to 2.61).
- No severe adverse events occurred during the study.
- Our results confirm the LDL-C-lowering properties of monacolin are clinically meaningful even in lower doses of 3 mg/day.
Liu X et al. • Nutrients (2023)
“However, it did not significantly affect serum TG, HDL-C, and CIMT.”
Key Findings:
- There were no significant differences in coagulation, liver function, renal function, or other indicators.
- No intervention-related adverse events, such as mouth ulcers, drooling, and stomach pain, were reported.
- The study results demonstrate that NMSs can ameliorate lipid levels (TC, LDL-C, non-HDL-C, and the LDL-C to HDL-C ratio) without the occurrence of adverse events.
- However, it did not significantly affect serum TG, HDL-C, and CIMT.
Study Type Distribution
Goals This Supplement Supports
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.